Get the Stockscreener App
90.14
1.36%
1.21
Blueprint Medicines Corp stock is traded at $90.14, with a volume of 1.09M.
It is up +1.36% in the last 24 hours and down -4.93% over the past month.
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
See More
Previous Close:
$88.93
Open:
$88.12
24h Volume:
1.09M
Relative Volume:
1.71
Market Cap:
$5.73B
Revenue:
$434.41M
Net Income/Loss:
$-128.05M
P/E Ratio:
-9.8085
EPS:
-9.19
Net Cash Flow:
$-250.52M
1W Performance:
-3.27%
1M Performance:
-4.93%
6M Performance:
-14.32%
1Y Performance:
+7.16%
1-Day Range:
$87.99
$90.99
1-Week Range:
$86.02
$98.41
52-Week Range:
$72.24
$121.90
Blueprint Medicines Corp Stock (BPMC) Company Profile
Name
Blueprint Medicines Corp
Sector
Industry
Phone
617-374-7580
Address
45 SIDNEY STREET, CAMBRIDGE, MA
Compare BPMC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BPMC
Blueprint Medicines Corp
|
90.14 | 5.73B | 434.41M | -128.05M | -250.52M | -2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Blueprint Medicines Corp Stock (BPMC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-24 | Initiated | JP Morgan | Overweight |
| Oct-24-24 | Initiated | UBS | Neutral |
| May-14-24 | Initiated | Stephens | Overweight |
| May-06-24 | Upgrade | Leerink Partners | Underperform → Market Perform |
| Oct-27-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-21-23 | Reiterated | Needham | Buy |
| Jul-31-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jun-05-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Jan-03-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-14-22 | Initiated | Needham | Buy |
| Nov-02-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-14-22 | Initiated | Berenberg | Buy |
| Jul-08-22 | Initiated | Oppenheimer | Outperform |
| Jun-27-22 | Initiated | Wells Fargo | Underweight |
| Jun-10-22 | Downgrade | Citigroup | Neutral → Sell |
| Jun-01-22 | Upgrade | Jefferies | Hold → Buy |
| Mar-01-22 | Initiated | Citigroup | Neutral |
| Feb-17-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jan-25-22 | Upgrade | Stifel | Hold → Buy |
| Nov-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-30-21 | Resumed | Stifel | Hold |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Mar-31-21 | Initiated | Credit Suisse | Neutral |
| Dec-03-20 | Initiated | Stifel | Hold |
| Nov-02-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-02-20 | Downgrade | Jefferies | Buy → Hold |
| Oct-30-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-15-20 | Reiterated | H.C. Wainwright | Buy |
| May-05-20 | Initiated | Barclays | Equal Weight |
| Mar-17-20 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-28-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-27-20 | Initiated | BMO Capital Markets | Market Perform |
| Nov-06-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-22-19 | Initiated | JMP Securities | Mkt Outperform |
| Oct-03-19 | Initiated | H.C. Wainwright | Buy |
| Sep-12-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-29-19 | Initiated | Piper Jaffray | Neutral |
| Aug-15-19 | Resumed | Raymond James | Mkt Perform |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| May-23-19 | Resumed | Goldman | Buy |
| Apr-03-19 | Initiated | Morgan Stanley | Overweight |
| Sep-25-18 | Initiated | Leerink Partners | Outperform |
| Dec-11-17 | Reiterated | Goldman | Buy |
View All
Blueprint Medicines Corp Stock (BPMC) Latest News
Blueprint Medicines director Jeffrey Albers sells $1.35 million in stock - Investing.com India
Blueprint Medicines COO Christina Rossi sells $218,098 in shares By Investing.com - Investing.com Australia
Blueprint Medicines COO Christina Rossi sells $218,098 in shares - Investing.com
Insider Sell: Christina Rossi Sells Shares of Blueprint Medicines Corp (BPMC) - GuruFocus.com
Blueprint Medicines Co. (NASDAQ:BPMC) Director Jeffrey W. Albers Sells 15,000 Shares - MarketBeat
Insider Selling: Blueprint Medicines Co. (NASDAQ:BPMC) COO Sells 2,274 Shares of Stock - MarketBeat
Blueprint Medicines (NASDAQ:BPMC) Shares Down 3.6%What's Next? - MarketBeat
Blueprint Medicines Corporation Seeks Validation of 2024 Stockholder Actions Through Section 205 Action - Defense World
Blueprint Medicines' SWOT analysis: stock's potential in precision oncology - Investing.com
Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference – Company Announcement - Financial Times
Geode Capital Management LLC Raises Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Insider Sells $169,639.94 in Stock - MarketBeat
Blueprint Medicines officer sells shares worth $169,635 - Investing.com
Blueprint Medicines officer sells shares worth $169,635 By Investing.com - Investing.com UK
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by Barclays PLC - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Sees Large Growth in Short Interest - MarketBeat
Blueprint Medicines' SWOT analysis: stock outlook amid Ayvakit success - Investing.com
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Bought by State Street Corp - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Zimmer Partners LP Makes New Investment in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by Castleark Management LLC - MarketBeat
Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting - Quantisnow
Holocene Advisors LP Sells 926,550 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Blueprint Medicines (FRA:2L9) Profitability Rank : 3 (As of Sep. 2024) - GuruFocus.com
Jacobs Levy Equity Management Inc. Buys 306,079 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines CEO Kate Haviland sells $227,304 in shares By Investing.com - Investing.com Australia
Blueprint Medicines CEO Kate Haviland sells $227,304 in shares - Investing.com
Erste Asset Management GmbH Purchases New Holdings in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Short Interest Down 5.3% in November - MarketBeat
The Manufacturers Life Insurance Company Has $13.88 Million Stake in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Exploring Three High Growth Tech Stocks in the United States - Simply Wall St
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Bought by Edgestream Partners L.P. - MarketBeat
Fred Alger Management LLC Sells 15,478 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Acquired by Charles Schwab Investment Management Inc. - MarketBeat
Fmr LLC Sells 316,913 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Buys Shares of 5,132 Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Eventide Asset Management LLC Grows Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines (BPMC) Up 8.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Alkeon Capital Management LLC Has $66.50 Million Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Purchased by Citigroup Inc. - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Purchased by Ally Bridge Group NY LLC - MarketBeat
Intech Investment Management LLC Takes Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Massachusetts Financial Services Co. MA Has $23.33 Million Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Pitcairn Co. Has $954,000 Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Acquires New Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines (FRA:2L9) EPS without NRI : €-4.43 (TTM As of Sep. 2024) - GuruFocus.com
Blueprint Medicines (FRA:2L9) Revenue per Share : €6.33 (TTM As of Sep. 2024) - GuruFocus.com
Blueprint Medicines (FRA:2L9) Operating Cash Flow per Share : €-3.56 (TTM As of Sep. 2024) - GuruFocus.com
Algert Global LLC Purchases 26,696 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by Eagle Asset Management Inc. - MarketBeat
Blueprint Medicines Corp Stock (BPMC) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):